Edwards Lifesciences Corporation
EW
$83.39
$0.951.15%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.60% | 9.14% | 8.23% | 8.57% | 4.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.60% | 9.14% | 8.23% | 8.57% | 4.48% |
| Cost of Revenue | 19.24% | 12.89% | 10.32% | 14.22% | 9.24% |
| Gross Profit | 8.40% | 8.18% | 7.71% | 7.20% | 3.34% |
| SG&A Expenses | 15.23% | 12.38% | 12.18% | 13.11% | 8.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 50.78% | 76.88% | 47.57% | -- | -187.27% |
| Total Operating Expenses | 16.52% | 14.59% | 10.77% | 12.38% | -0.83% |
| Operating Income | -2.46% | -2.78% | 2.15% | -0.45% | 18.47% |
| Income Before Tax | 3.11% | 7.75% | 15.38% | 12.80% | 4.14% |
| Income Tax Expenses | 67.12% | 43.96% | 14.80% | -0.20% | -21.26% |
| Earnings from Continuing Operations | -3.42% | 3.66% | 15.45% | 14.43% | 7.69% |
| Earnings from Discontinued Operations | -99.07% | 2,331.11% | 1,539.00% | 1,446.10% | 1,840.48% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 42.11% | 66.67% | 43.59% | 63.33% | 35.71% |
| Net Income | -67.11% | 181.58% | 195.71% | 197.68% | 190.65% |
| EBIT | -2.46% | -2.78% | 2.15% | -0.45% | 18.47% |
| EBITDA | -1.86% | -2.54% | 2.27% | 0.22% | 17.12% |
| EPS Basic | -66.47% | 185.96% | 200.24% | 202.32% | 195.52% |
| Normalized Basic EPS | -4.01% | -0.97% | 6.57% | 4.58% | 21.99% |
| EPS Diluted | -66.58% | 186.40% | 200.96% | 203.88% | 196.91% |
| Normalized Diluted EPS | -3.86% | -0.75% | 6.78% | 4.75% | 22.25% |
| Average Basic Shares Outstanding | -2.40% | -2.28% | -1.85% | -1.48% | -1.16% |
| Average Diluted Shares Outstanding | -2.55% | -2.50% | -2.06% | -1.67% | -1.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |